NCT07839884Not yet recruitingPhase 3
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF TILREKIMIG IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long Period of Time.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1360 (estimated)
- First submitted
- 18 Sept 2026
- Start date
- 21 Sept 2026
- Primary completion date
- 12 May 2034
- Lead sponsor
- Pfizer
- Diseases
- COPD
- NCT number
- NCT07839884
- EU CT number
- 2026-528166-19-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 1360
- From 21 Sept 2026 to the primary completion date, 12 May 2034
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Medical, laboratory, psychiatric, or behavioral condition that increases risk or interferes with study participation.
Other
- Ongoing safety-significant AE.
- Parent-study SAE incompatible with continued participation.
- Pregnancy or breastfeeding.
Who the study is looking for
- Participants who completed parent study C4531031.
- Individuals of childbearing potential must be willing to use a highly effective method of contraception.
Age in the registry: 35 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.